The New York Times Is Now Engulfed in the STAR*D Scandal
The New York Times published yet again the fraudulent result from the STAR*D trial. Will the mainstream media ever tell of this scandal?
Source: madinamerica.com
📰 Quick Inventory News
Quick Inventory News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Quick Inventory. Real-time updates on events, politics, business and more.
Severity of TRD Predicts Ketamine vs ECT Response
The severity of TRD appeared to predict response to IV ketamine vs ECT. However, experts said more research is needed before drawing any definitive conclusions.
United States University Of Texas Southwestern Medical Center Manish Jha Amit Anand At Harvard Medical School Depression Association Of America Texas Southwestern Medical Center
Source: medscape.com
STAR*D: It's Time to Atone and Retract
“Our patients, our field, and our integrity demand a better explanation of what happened in STAR*D than what has thus been provided.”
Source: psychiatrictimes.com
Impact of Psychiatric Follow-Up Frequency on Outcomes and Waiting Times
Naturally occurring variations in appointment frequencies do not appear to have a major impact on clinical outcomes, but they significantly affect waiting times.
Source: ajmc.com
STAR*D Dethroned?
Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?
New Hampshire United States Exeter Hospital Nikolai Adobestock University Of Connecticut Insight Meditation Society
Source: psychiatrictimes.com
Psilocybin Shows Promise in Treatment-Resistant Bipolar Type II Depression
Most patients achieved remission in small trial, and no hypomania episodes occurred
New York United States David Yaden Johns Hopkins University School Of Medicine Depression Rating Scale Medpage Today
Source: medpagetoday.com
The STAR*D Scandal: Scientific Misconduct on a Grand Scale
In the STAR*D study, NIMH investigators committed research fraud. The final outcomes paper needs to be retracted.
Source: madinamerica.com
Cognitive Biotype, New Depression Subtype, Resistant to Common Antidepressants
A new subtype of depression, the cognitive biotype, affects 27% of patients with depression who respond poorly to prescribed antidepressants.
International Study Predict Optimized Treatment Hamilton Rating Scale Quick Inventory Depressive Symptomatology
Source: psychiatryadvisor.com
New Data Reveal the Full Extent of STAR*D Failure
The initial STAR*D study, which has been used to promote antidepressants, employed outcome switching to hide poor results.
Source: madinamerica.com
Cognitive Biotype, New Depression Subtype, Resistant to Common Antidepressants
A new subtype of depression, the cognitive biotype, affects 27% of patients with depression who respond poorly to prescribed antidepressants.
International Study Predict Optimized Treatment Hamilton Rating Scale Quick Inventory Depressive Symptomatology
Source: neurologyadvisor.com